BAYER AG

Global Food Biotechnology market to grow from 25.0 Billion USD in 2024 to 50.0 Billion USD by 2032, with a CAGR of 9%. Key players include BASF, Bayer, Syngenta, and others. Market segmented by Types (GMOs, Fermentation, Synthetic Biology, Plant Cell Culture) and Applications (Food Processing, Nutrient Enrichment, Disease Resistance, Flavor Enhancement). Dominating region: North America; fastest-growing region: Asia-Pacific.

Small molecule therapies remain crucial; FDA approves BMS's Cobenfy for schizophrenia, Gilead licenses lenacapavir for HIV, ARS's neffy for anaphylaxis, AstraZeneca's Tagrisso for lung cancer, Bayer's darolutamide for prostate cancer, Novartis' Kisqali for breast cancer, and Pfizer withdraws voxelotor for sickle cell disease due to safety concerns.

Authors from various institutions collaborated on a project, with A.R.M.B. and M.F.E. as originators. Experimental work was conducted by C.L.L. and F.F., and data processing by M.F.E. and L.S. Additional contributors participated in experiments and manuscript editing.

Eli Lilly invests $212 million to expand its Suzhou plant, following China's approval of its weight loss drug Zepbound. Other pharmaceutical giants like Bayer and Roche also expand in China, highlighting the sector's resilience amid economic challenges. China's healthcare sector reforms and large market attract foreign investment, despite pricing pressures and competition from local firms. Multinationals increasingly partner with Chinese biotech companies for innovation and market access.

Aignostics raised $34 million in Series B financing to build new biopharmaceutical products, expand in the US, and develop foundation models with Mayo Clinic. The funding supports AI-driven pathology advancements for drug development and diagnostics.

FDA approves oxycodone hydrochloride for severe pain, sulopenem etzadroxil and probenecid for uncomplicated UTIs, Pfizer's Abrysvo for RSV in adults 18-59, marstacimab-hncq for hemophilia B, Imuldosa biosimilar to Stelara, Bayer's elinzanetant for menopause symptoms, and gepotidacin for uncomplicated UTI.

Q3 2024 revenues up 11% to $3.72 billion; Dupixent global net sales by Sanofi up 23% to $3.82 billion; U.S. net sales for EYLEA HD and EYLEA up 3% to $1.54 billion; Libtayo global net sales up 24% to $289 million; GAAP diluted EPS up 30% to $11.54; FDA approves Dupixent for COPD and eosinophilic phenotype; positive results for Dupixent in CSU and BP trials.

Researchers at Broad Institute developed BRD-810, a compound that reactivates apoptosis in tumor cells by inhibiting MCL1, with rapid clearance minimizing side effects. Tested in various cancer models, BRD-810 showed efficacy without cardiac toxicity, positioning it for potential clinical trials.

Bayer and Liveo Research introduce PET blister packaging for Aleve, reducing carbon footprint by 38% and eliminating PVC use, with plans to expand globally.

The red biotechnology market is projected to grow from $509.71 billion in 2023 to $867.20 billion by 2028, driven by advancements in personalized medicine, biosimilars, and genetic engineering. Major players include Pfizer, Roche, Bayer, and Amgen.